Financial Engines Advisors
STRO icon

Financial Engines Advisors’s Sutro Biopharma STRO Stock Holding History

Financial Engines Advisors’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,015
Closed -$231K – 258
2021
Q1 		$231K Buy
+1,015
New +$241K ﹤0.01% 247

Other funds holding STRO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Financial Engines Advisors's STRO Position: Q2 2021 in Review

Financial Engines Advisors sold out of Sutro Biopharma (STRO) in Q2 2021, closing a stake of 1,015 shares — an estimated $231K sold.

Financial Engines Advisors first reported a position in STRO in Q1 2021 and held it in 1 quarter. The position peaked at $231K in Q1 2021. 124 funds tracked by Wall St. Rank hold STRO as of Q2 2021.

  • Financial Engines Advisors reported no remaining Sutro Biopharma position as of Q2 2021 after selling out during the quarter.
  • Financial Engines Advisors sold 1,015 Sutro Biopharma shares in Q2 2021, an estimated $231K.
  • Financial Engines Advisors first reported a position in Sutro Biopharma in Q1 2021 and held it in 1 quarter.
  • Financial Engines Advisors's Sutro Biopharma position peaked at $231K in Q1 2021.
  • 124 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2021.

Based on Financial Engines Advisors's 13F filing for Q2 2021, filed 12 Aug 2021.